Highly active antiretroviral therapy and survival in HIV-infected injection drug users

JAMA

Volumn 300, Issue 5, 2008, Pages 550-554

  Wood, Evan ^a   Hogg, Robert S ^b   Lima, Viviane Dias ^a   Kerr, Thomas ^a   Yip, Benita ^d   Marshall, Brandon D L ^d   Montaner, Julio S G ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION DRUG USER; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL RATE;

EID: 48749086250     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.5.550     Document Type: Article

References (27)

1. Hammer SM, Squires KE, Hughes MD, et al; AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337(11):725-733.
2. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med. 2003;139(10):810-816.
3. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-129.
4. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66(6):769-789.
5. Wood E, Kerr T, Montaner JS. HIV treatment, injection drug use, and illicit drug policies. Lancet. 2007;370(9581):8-10.
6. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007;18(4):255-261.
7. Aceijas C, Oppenheimer E, Stimson GV, Ashcroft RE, Matic S, Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "treating 3 million by 2005: making it happen: the WHO strategy" ("3 by 5"). Addiction. 2006;101(9):1246-1253.
8. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15(9):1115-1123.
9. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281(24):2305-2315.
10. Wood E, Montaner JS, Schechter MT, Tyndall MW, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated HIV-1 infection in the era of modern antiretroviral therapy. J Infect Dis. 2003;188(8):1164-1170.
11. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am. 2007;21(1):149-179.
12. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22(4):369-378.
13. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDS. 2001;15(4):185-191.
14. Loughlin A, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M, Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care. 2004;16(4):485-500.
15. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165(6):618-623.
16. Mocroft A, Gatell J, Reiss P, et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS. 2004;18(17):2333-2337.
17. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568-2577.
18. World Health Organization. International Statistical Classification of Diseases and Related Health Problems version for 2007. http://www.who.int/ classifications/apps/icd/icd10online/. Accessibility verified June 26, 2008.
19. Collett D. Modelling Survival Data in Medical Research. New York, NY: Chapman & Hall; 1994.
20. Allison PD. Survival Analysis Using SAS: A Practical Guide. 7th ed. Cary, NC: SAS Press; 2004.
21. Parmar MK, Machin D. Survival Analysis: A Practical Approach. New York, NY: Wiley; 1995.
22. Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194(8):1108-1114.
23. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175-1183.
24. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138(11):923-936.
25. Public Health Agency of Canada. Estimates of HIV prevalence and incidence in Canada 2005. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/dr3215ea. html. Accessed May 25, 2006.
26. Tyndall MW, McNally M, Lai C, et al. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy. 2007;18(4):281-287.
27. Ball AL. Universal access to HIV/AIDS treatment for injecting drug users: keeping the promise. Int J Drug Policy. 2007;18(4):241-245.